SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111-1116.
  • 2
    Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010;28:1106-1111.
  • 3
    Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011;29:1517-1524.
  • 4
    Bekelman JE, Mitra N, Efstathiou J, et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer [serial online]. Int J Radiat Oncol Biol Phys. 2011;81:e325-e334.
  • 5
    Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611-1620.
  • 6
    Kim S, Shen S, Moore DF, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol. 2011;60:908-916.
  • 7
    Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013;105:25-32.
  • 8
    Deville C, Ben-Josef E, Vapiwala N. Radiation therapy modalities for prostate cancer [letter]. JAMA308:451, 2012; author reply 451-452.
  • 9
    Mendenhall NP, Schild S, Slater J. Radiation therapy modalities for prostate cancer [letter]. JAMA. 2012;308:450-451; author reply 451-452.
  • 10
    Szymanski KM, Wei JT, Dunn RL, et al. Development and validation of an abbreviated version of the Expanded Prostate Cancer Index Composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76:1245-1250.
  • 11
    Mendenhall NP, Li Z, Hoppe BS, et al. Early outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:213-221.
  • 12
    Sandler HM, Liu PY, Dunn RL, et al. Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study. Urology. 2010;75:1004-1008.
  • 13
    Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899-905.
  • 14
    Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005;23:2772-2780.
  • 15
    Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582-592.
  • 16
    Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250-1261.
  • 17
    Hoppe BS, Nichols RC, Henderson RH, et al. Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer. 2012;118:4619-4626.
  • 18
    Fiorino C, Fellin G, Rancati T, et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 2008;70:1130-1137.
  • 19
    Gray PJ, Paly JJ, Yeap BY, et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013;119:1729-1735.
  • 20
    Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001;39:1118-1130.
  • 21
    Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:744-751.
  • 22
    Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007;69:444-453.
  • 23
    Tucker SL, Dong L, Michalski JM, et al. Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06. Int J Radiat Oncol Biol Phys. 2012;84:390-395.
  • 24
    Peeters ST, Lebesque JV, Heemsbergen WD, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2006;64:1151-1161.
  • 25
    al-Abany M, Helgason AR, Cronqvist AK, et al. Toward a definition of a threshold for harmless doses to the anal-sphincter region and the rectum. Int J Radiat Oncol Biol Phys. 2005;61:1035-1044.
  • 26
    Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436-445.
  • 27
    Hamstra DA, Stenmark MJ, Ritter T, et al. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85:1246-1253.
  • 28
    Krol R, Smeenk RJ, van Lin EN, et al. Impact of late anorectal dysfunction on quality of life after pelvic radiotherapy. Int J Colorectal Dis. 2013;28:519-526.
  • 29
    Yeoh EK, Holloway RH, Fraser RJ, et al. Pathophysiology and natural history of anorectal sequelae following radiation therapy for carcinoma of the prostate [serial online]. Int J Radiat Oncol Biol Phys. 2012;84:e593-e599.